Furthermore, LOY has also emerged as a potential biomarker for predicting responses to ICB therapies; LOY in tumor cells has been correlated with improved responses to anti-PD-L1 therapy in BC patients [117], suggesting its potential utility in guiding treatment decisions. Here, CD274 is linked to breast cancer.